Docoh
Loading...

ATOS Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.

ATOS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Nov 21
2 Dec 21
31 Dec 21
Quarter (USD)
Sep 21 Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 140.15M 140.15M 140.15M 140.15M 140.15M 140.15M
Cash burn (monthly) 797.35K (positive/no burn) 1.73M 1.94M 1.02M 1.35M
Cash used (since last report) 1.67M n/a 3.62M 4.05M 2.13M 2.83M
Cash remaining 138.49M n/a 136.53M 136.1M 138.02M 137.33M
Runway (months of cash) 173.7 n/a 78.8 70.2 135.2 101.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Jul 21 Gregory L Weaver Common Stock Sell Dispose S No No 5.58 107,497 599.83K 0
2 Jul 21 Gregory L Weaver Common Stock Payment of exercise Dispose F No No 6.4 57,084 365.34K 107,497
2 Jul 21 Gregory L Weaver Common Stock Option exercise Acquire M No No 1.7 70,000 119K 164,581
2 Jul 21 Gregory L Weaver Common Stock Option exercise Acquire M No No 2.52 45,000 113.4K 94,581
2 Jul 21 Gregory L Weaver Common Stock Option exercise Acquire M No No 2.38 45,000 107.1K 49,581
2 Jul 21 Gregory L Weaver Common Stock Option exercise Acquire M No No 5.64 4,581 25.84K 4,581
2 Jul 21 Gregory L Weaver Stock Option Common Stock Option exercise Dispose M No No 1.7 70,000 119K 0
2 Jul 21 Gregory L Weaver Stock Option Common Stock Option exercise Dispose M No No 2.52 45,000 113.4K 0
2 Jul 21 Gregory L Weaver Stock Option Common Stock Option exercise Dispose M No No 2.38 45,000 107.1K 0
2 Jul 21 Gregory L Weaver Stock Option Common Stock Option exercise Dispose M No No 5.64 4,581 25.84K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

32.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 101 99 +2.0%
Opened positions 20 60 -66.7%
Closed positions 18 19 -5.3%
Increased positions 29 20 +45.0%
Reduced positions 25 7 +257.1%
13F shares
Current Prev Q Change
Total value 144.99M 234.63M -38.2%
Total shares 40.92M 45.58M -10.2%
Total puts 1.83M 5.98M -69.3%
Total calls 4.45M 7.92M -43.8%
Total put/call ratio 0.4 0.8 -45.4%
Largest owners
Shares Value Change
BLK Blackrock 9.55M $31.14M +6.7%
Vanguard 7.06M $23M +22.5%
Empery Asset Management 3.8M $3.5M 0.0%
CVI Investments 3.8M $3.5M 0.0%
Intracoastal Capital 2.25M $1.94M 0.0%
STT State Street 2.15M $7M +5.6%
Geode Capital Management 2.11M $6.88M +7.1%
Nuveen Asset Management 1.59M $5.71M +45.3%
NTRS Northern Trust 1.08M $3.53M -3.7%
Citadel Advisors 1.02M $3.33M NEW
Largest transactions
Shares Bought/sold Change
Susquehanna International 247.02K -2.35M -90.5%
IVZ Invesco 37.09K -1.81M -98.0%
Group One Trading 0 -1.64M EXIT
Millennium Management 264.02K -1.4M -84.2%
Vanguard 7.06M +1.29M +22.5%
Jane Street 219.74K -1.1M -83.4%
Sabby Management 0 -1.05M EXIT
Citadel Advisors 1.02M +1.02M NEW
D. E. Shaw & Co. 896.06K +896.06K NEW
BLK Blackrock 9.55M +596.34K +6.7%

Financial report summary

?
Management Discussion
  • We are a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer, other breast conditions and COVID-19. Our drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings: one to reduce tumor cell activity in breast cancer patients in the “window of opportunity” between diagnosis of breast cancer and surgery; and another for women with dense breast tissue to reduce the density. Our two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Our business strategy is to advance our programs through clinical studies including with partners, and opportunistically add programs in areas of high unmet medical need through acquisition, collaboration, or internal development.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: die, driven, headcount, injury, NaN, neoadjuvant, Similarly
Removed: absence, blood, COVID, cytopathic, diagnosed, discover, excluding, hot, hydroxychloroquine, Maxim, microscopic, MPA, night, observe, Potency, potent, preparing, recurrence, remdesivir, responding, vasomotor